Resergene Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-01-2025
- Paid Up Capital ₹ 0.56 M
as on 04-01-2025
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -96.78%
(FY 2021)
- Profit -3311.82%
(FY 2021)
- Ebitda -3576.15%
(FY 2021)
- Net Worth -37.22%
(FY 2021)
- Total Assets -88.77%
(FY 2021)
About Resergene Biosciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.56 M, as per Ministry of Corporate Affairs (MCA) records.
Basavapatna Venkataramiah and Aswini Pujahari serve as directors at the Company.
- CIN/LLPIN
U24100KA2014PTC074673
- Company No.
074673
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jun 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Resergene Biosciences Private Limited offer?
Resergene Biosciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Weight Loss Supplement, Nutraceuticals, Nutritional Supplements, Biscuit, Nutrichoice Biscuit, Diabetic Biscuits, Fitness Supplements, Medical Laboratory Instruments, VTM Kit Raw Materials.
Who are the key members and board of directors at Resergene Biosciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Basavapatna Venkataramiah  | Director | 02-Jun-2014 | Current |
| Aswini Pujahari | Director | 31-Mar-2016 | Current |
Financial Performance of Resergene Biosciences.
Resergene Biosciences Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 96.78% decrease. The company also saw a substantial fall in profitability, with a 3311.82% decrease in profit. The company's net worth observed a substantial decline by a decrease of 37.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Resergene Biosciences?
In 2021, Resergene Biosciences had a promoter holding of 80.09% and a public holding of 19.91%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bolangir Institute Of Medical Science LimitedActive 2 years 9 monthsAswini Pujahari is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Resergene Biosciences?
Unlock and access historical data on people associated with Resergene Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Resergene Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Resergene Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
